Navigation Links
GEN Reports on Novel Hit-to-Lead Drug Discovery Strategies
Date:7/8/2008

NEW ROCHELLE, N.Y., July 8 /PRNewswire/ -- Biotech and pharmaceutical firms are developing a host of new technologies designed to streamline the complicated drug discovery process, reports Genetic Engineering and Biotechnology News (GEN). Most successful approaches rely on a combination of high-throughput screening methods, miniaturization techniques, and advanced data-analysis tools, according to an article in the July issue (http://www.genengnews.com/articles/chitem.aspx?aid=2527) of GEN.

"The key goal for companies trying to develop new drugs is to find the best series of compounds that will optimize their chances of turning promising hits into even more promising leads," notes John Sterling, Editor in Chief of GEN.

Merck, for example, tries to make certain that its scientists work on physiologically relevant targets and assays during early-stage drug discovery research. For target identification the company uses RNAi technology in human cell lines. Multiparametric assays then generate biological activity profiles that can often provide valuable insight into complex disease models.

Pharmacopeia's screening platform is based on its ECLiPS(R) (encoded combinatorial libraries on polymeric support) technology. Three steps are involved in the firm's screening process. A primary high-throughput approach screens eluate from multiple beads. A follow-up protocol screens single bead eluates from those sublibraries, which demonstrate activity in the assay. Finally, company scientists submit beads for a decoding process, which is how they identify the structure of compounds in the active wells in step two.

Also discussed in the GEN article is drug discovery activities taking place at GlaxoSmithKline, Fujifilm, Archemix, and the Southern Research Institute.

For a copy of the July issue of GEN, please call (914) 740-2122, or email:

SOURCE Genetic Engineering and Biotechnology News
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Galaxy Nutritional Foods Reports FY2008 Results
2. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
4. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
8. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
11. Advance Nanotech Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is pleased to announce that ... has added two more  consultants to its team ... PPL-003 uses a new proprietary cell permeable peptide ... its anti-inflammatory cargo into the eye. ...
(Date:9/23/2014)... , September 23, 2014 ... Closed System Transfer     Devices  (CSTD) ... partnership with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s leading ... Taiwan , China ... the company continues to expand globally, and throughout ...
(Date:9/23/2014)... New York (PRWEB) September 23, 2014 ... from around the globe will convene at ... International Conference, to be held October 26-28 ... in evidence-based research and practice in individualized ... physicians, scientists, researchers, nurses, psychologists, nutritionists, naturopaths, ...
(Date:9/22/2014)... 2014 Pearl's Premium Ultra Low Maintenance ... tolerant grass seed this week with the release of ... coincides with the fact that it is time to ... believe. , As of the date 6/4/13, Pearl's ... by industry experts and the media including: The ...
Breaking Biology Technology:Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2
... BRISBANE, Australia and SEATTLE, Feb. 24 Implicit,Bioscience ... antibody IC14 from Eli Lilly and Company. Implicit ... to Lilly. Lilly will also,receive a royalty on ... "Implicit Bioscience brings substantial expertise and passion to ...
... Feb. 24 Nektar Therapeutics,(Nasdaq: NKTR ... fourth quarter and,year ended December 31, 2008. , ... year for Nektar," said Howard W. Robin,President and ... unique polymer,conjugation chemistry platform, we advanced numerous proprietary ...
... proteinTHOUSAND OAKS, Calif., Feb. 24 Bone Biologics, Inc. ... Aragen Bioscience, has completed development of a recombinant cell ... protein. Bone Biologics has been developing the protein as ... years of research in the lab performed by the ...
Cached Biology Technology:Implicit Licenses Clinical Stage Antibody Program From Lilly 2Implicit Licenses Clinical Stage Antibody Program From Lilly 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences 2
(Date:9/22/2014)... Manufacturing biofuels from food crop by-products such as straw ... work of scientists in the UK and France. ... Research Council (BBSRC) have discovered variant straw plants whose ... biofuels, but which are not significantly smaller or weaker ... ease pressure on global food security as biofuels from ...
(Date:9/22/2014)... their own "antifreeze" proteins to survive in the ... effect, researchers report: The protein-bound ice crystals that ... temperatures warm. , The finding is reported ... of Sciences . , "We discovered what appears ... of antifreeze proteins in Antarctic notothenioid fishes," said ...
(Date:9/22/2014)... of seven institutions in the country selected by ... this year,s BEST Award a $2 million ... most promising biomedical sciences graduate trainees to career ... they have traditionally taken. , The award funds ... Biomedical Scientists (iJOBs) program. It includes courses, seminars, ...
Breaking Biology News(10 mins):Plant variants point the way to improved biofuel production 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3
... relatively common to come across petrol stations surrounded by houses, ... (UM) have studied the effects of contamination at petrol stations ... in buildings less than 100 metres from the service stations. ... increases the risk of cancer have been recorded at ...
... has been awarded a $2.3 million grant by the ... focusing on developing a novel stem cell based therapy ... studying human induced pluripotent stem (iPS) cells derived from ... in the lab and investigate the role of inflammation ...
... not-so-distant evolutionary past, stress often meant imminent danger, ... of our body,s stress response is to stock-pile ... Unit (MMPU), a collaboration between the European Molecular ... University of Heidelberg Medical Centre, have discovered how ...
Cached Biology News:Petrol stations pollute their immediate surroundings 2Stem cell leader awarded $2.3 million grant for Parkinson's 2Blood-clotting protein linked to cancer and septicemia 2Blood-clotting protein linked to cancer and septicemia 3
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
...
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
Permeabilization Solution, 5X...
Biology Products: